دورية أكاديمية
Clinical impact of 99m Tc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patients.
| العنوان: | Clinical impact of 99m Tc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patients. |
|---|---|
| المؤلفون: | Bucalau AM; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium. Ana-Maria.Bucalau@hubruxelles.be., Collette B; Department of Nuclear Medicine, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium. Benoit.Collette@hubruxelles.be., Tancredi I; Department of Radiology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Vouche M; Department of Radiology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Pezzullo M; Department of Radiology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Bouziotis J; Department of Biomedical Research, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Moreno-Reyes R; Department of Nuclear Medicine, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Trotta N; Department of Nuclear Medicine, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Levillain H; Department of Nuclear Medicine, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Van Laethem JL; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium., Verset G; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Erasme/Bordet Institute-Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium. |
| المصدر: | European journal of hybrid imaging [Eur J Hybrid Imaging] 2023 Jul 07; Vol. 7 (1), pp. 12. Date of Electronic Publication: 2023 Jul 07. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SpringerOpen Country of Publication: England NLM ID: 101724113 Publication Model: Electronic Cited Medium: Internet ISSN: 2510-3636 (Electronic) Linking ISSN: 25103636 NLM ISO Abbreviation: Eur J Hybrid Imaging Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London, United Kingdom : SpringerOpen, [2017]- |
| مستخلص: | Background: Recent data demonstrated that personalized dosimetry-based selective internal radiotherapy (SIRT) is associated with better outcome for unresectable hepatocellular carcinoma (HCC). Aim: We aim to evaluate the contribution of personalized predictive dosimetry (performed with Simplicity 90 ® software) in our population of HCC patients by comparing them to our historical cohort whose activity was determined by standard dosimetry. Methods: This is a retrospective, single-center study conducted between February 2016 and December 2020 that included patients with HCC who received SIRT after simulation based on either standard dosimetry (group A) or, as of December 2017, on personalized dosimetry (group B). Primary endpoints were best overall response (BOR) and objective response rate (ORR) evaluated by mRECIST at 3 months. Safety and toxicity profiles were evaluated at 1- and 3-months post-treatment. For group A we compared the activity to be administered determined a posteriori using Simplicit 90 Y® and the activity actually administered determined by the standard approach. Results: Between February 2016 and December 2020, 66 patients received 69 simulations leading to 40 treatments. The median follow-up time was equal for both groups, 21 months (range 3-55) in group A and 21 months (range 4-39) in group B. The per patient analysis revealed a significant benefit of personalized predictive dosimetry in terms of better overall response at 3 months (80% vs. 33.3%, p = 0.007) and at 6 months (77.8% vs. 22.2%, p = 0.06). This trend was found in the analysis by nodule with a response rate according to mRECIST of 87.5% for personalized dosimetry versus 68.4% for standard dosimetry at 3 months, p = 0.24. Only one grade 3 biological toxicity (hyperbilirubinemia) was noted in group A. The comparison between the administered activity and the recommended activity recalculated a posteriori using Simplicit 90 Y® showed that the vast majority of patients who progressed (83.33%) received less activity than that recommended by the personalized approach or an inadequate distribution of the administered activity. Conclusions: Our study aligns to recent literature and confirms that the use of personalized dosimetry allows a better selection of HCC patients who can benefit from SIRT, and consequently, improves the effectiveness of this treatment. (© 2023. The Author(s).) |
| References: | Lancet Oncol. 2017 Dec;18(12):1624-1636. (PMID: 29107679) Ann Oncol. 2013 Oct;24(10):2565-2570. (PMID: 23857958) Eur J Nucl Med. 1997 Mar;24(3):293-8. (PMID: 9143467) J Hepatol. 2022 Apr;76(4):874-882. (PMID: 34856322) Med Phys. 2022 Dec;49(12):7567-7582. (PMID: 35894818) Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699. (PMID: 35146577) Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. (PMID: 26338177) Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):798-806. (PMID: 31399801) J Nucl Med. 2016 Nov;57(11):1672-1678. (PMID: 27307346) J Nucl Med. 2015 Nov;56(11):1654-60. (PMID: 26315830) Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1695-1704. (PMID: 31098749) Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. (PMID: 33166497) Br J Radiol. 1997 Aug;70(836):823-8. (PMID: 9486047) Med Phys. 2011 Aug;38(8):4824-45. (PMID: 21928655) J Nucl Med. 2013 Apr;54(4):516-22. (PMID: 23447653) J Clin Oncol. 2018 Jul 1;36(19):1913-1921. (PMID: 29498924) Semin Liver Dis. 2010 Feb;30(1):52-60. (PMID: 20175033) Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584. (PMID: 33433699) Eur J Nucl Med. 1999 Jul;26(7):699-704. (PMID: 10398817) Liver Int. 2017 Jan;37(1):101-110. (PMID: 27514012) J Nucl Med. 2013 Aug;54(8):1294-301. (PMID: 23749996) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) Radiology. 2020 Sep;296(3):673-684. (PMID: 32602828) J Vasc Interv Radiol. 2015 Nov;26(11):1615-21. (PMID: 26321017) Hepatology. 2021 Nov;74(5):2342-2352. (PMID: 33739462) Biomaterials. 2001 Nov;22(22):3073-81. (PMID: 11575483) |
| فهرسة مساهمة: | Keywords: 99mTc-MAA scintigraphy; Hepatocellular carcinoma; Selective Internal RadioTherapy; Transarterial radioembolization |
| تواريخ الأحداث: | Date Created: 20230706 Latest Revision: 20231101 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10326228 |
| DOI: | 10.1186/s41824-023-00171-8 |
| PMID: | 37414964 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2510-3636 |
|---|---|
| DOI: | 10.1186/s41824-023-00171-8 |